

HEREDITARY ANGIOEDEMA AGENTS PRIOR AUTHORIZATION FORM (form effective 1/8/2024)

Prior authorization guidelines for **Hereditary Angioedema (HAE) Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

	1	- I				
New request Renewal request # of pages:		Prescriber name:				
Nove of effect contact		Specialty				
Name of office contact:		Specialty:				
Contact's phone number:		NPI: State license #:				
contacts profits number.						
LTC facility		Street address:				
contact/phone:						
Beneficiary name:		City/state/zip:				
Beneficiary ID#:	eneficiary ID#: DOB: Phone:		Phone:		Fax:	
CLINICAL INFORMATION						
Drug requested:		Strength: Dosa		sage form:		
Dose/directions:		Quantity: Refills:		Refills:		
Diagnoses (submit documentation):		Dx codes (<u>required</u>):				
Has the beneficiary been taking the reque	t 90 days?		Submit documentation and date			
, , ,	,	No of last dose.				
Is the requested medication prescribed by or in consultation with an allergist/immunologis			☐Yes Submit documentation of			
dermatologist, or hematologist?			□No	consultation, if ap	plicable.	
Will the beneficiary be using the requested medication with any other HAE Agents for the same			☐Yes – please list:			
indication (ie, more than 1 HAE Agent for	an 1 HAE Agent for <u>long-</u>					
term prophylaxis)?		□No				
Complete all sections that apply to the beneficiary and this request.						
Check all that apply and submit documentation for each item.						
INITIAL requests						
Requested medication is being used for short-term prophylaxis (e.g., surgical or dental procedure)						
☐ Has a diagnosis of HAE Type I or Type II (with C1 inhibitor deficiency/dysfunction) AND:						
Has a low C4 complement level (mg/dL) obtained on 2 separate occasions						
☐At least one of the following:						





☐ Has a low C1 esterase inhibitor antigenic level (mg/dL) obtained on 2 separate occasions				
Has a low C1 esterase inhibitor functional level (<65% [unless already using an androgen or C1 esterase inhibitor]) obtained on 2				
separate occasions				
☐ Has a diagnosis of HAE Type III (with normal C1 inhibitor) AND:				
☐ Has a normal C4 complement level (mg/dL)				
☐ Has a normal C1 esterase inhibitor antigenic level (mg/dL)				
☐ Has a normal C1 esterase inhibitor functional level				
☐ Has a history of recurrent angioedema without urticaria				
One of the following:				
☐Both of the following:				
☐ Has a family history of HAE				
Failed to respond to maximum recommended doses of antihistamines (eg, cetirizine 20 mg twice daily)				
☐ Has an HAE-causing genetic mutation				
One of the following:				
☐ Is <u>not</u> taking an estrogen-containing medication (hormone replacement, contraceptives, etc.)				
Is taking an estrogen-containing medication (hormone replacement, contraceptives, etc.) that is medically necessary for the				
beneficiary's indication – specify indication:				
☐ Is <u>not</u> taking an ACE inhibitor (benazepril, enalapril, lisinopril, quinapril, ramipril, etc.)				
☐ Is using the requested medication for long-term prophylaxis AND:				
☐ Has poorly controlled HAE despite use of an HAE Agent for on demand/acute treatment				
☐For a non-preferred HAE Agent:				
Has a history of trial and failure of or contraindication or intolerance to the preferred agents in this class that are approved or medically				
accepted for treatment of the beneficiary's condition (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-				
preferred agents in this class.)				
RENEWAL requests				
Is using the requested medication for <u>long-term prophylaxis</u> AND:				
Experienced fewer HAE attacks since starting the requested medication				
☐ Is using the requested medication for <u>acute treatment</u> AND:				
Experienced a positive clinical response to the requested medication				
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION				
Prescriber Signature:	Date:			
riescriber signature.	Date.			

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.